Antibody-drug conjugates (ADCs) have emerged as a revolutionary therapeutic class,
combining the precise targeting ability of monoclonal antibodies with the potent cytotoxic …

Proteolysis-targeting chimeras (PROTACs) have been an area of intensive research with the
potential to extend drug space not target to traditional molecules. In the last half decade, we …

Cancer is one of the most common causes of death. So, its lethal effect increases with time.
Near about hundreds of cancers are known in humans. Cancer treatment is done to cure or …

Sarcomas are heterogeneous bone and soft tissue cancers representing the second most
common tumor type in children and adolescents. Histology and genetic profiling discovered …

The scientific community has shown considerable interest in proteolysis-targeting chimeras
(PROTACs) in the last decade, indicating their remarkable potential as a means of achieving …

Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules consisting of
two ligands joined by a linker, enabling them to simultaneously bind with an E3 ligase and a …

Autophagy-targeting chimera (AUTAC) has emerged as a powerful modality that can
selectively degrade tumor-related pathogenic proteins, but its low bioavailability and …

Autophagy plays a vital role in sustaining cellular homeostasis and its alterations have been
implicated in the etiology of many diseases. Drugs development targeting autophagy began …

The development of miniaturized high‐throughput in situ screening platforms capable of
handling the entire process of drug synthesis to final screening is essential for advancing …

Alkenyl oxindoles have been characterized as autophagosome-tethering compounds
(ATTECs), which can target mutant huntingtin protein (mHTT) for lysosomal degradation. In …